Market Place
Sourcing Support
LAVA Therapeutics to Participate in H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
LAVA Reports Second Quarter 2024 Financial Results and Business Update
20 Aug 2024 //
GLOBENEWSWIRE
LAVA To Join H.C. Wainwright 2nd Annual Immune Cell Engager Conference
20 Jun 2024 //
GLOBENEWSWIRE
LAVA Announces Annual Meeting of Shareholders
10 Jun 2024 //
GLOBENEWSWIRE
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
21 May 2024 //
GLOBENEWSWIRE
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
06 May 2024 //
GLOBENEWSWIRE
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052
05 Mar 2024 //
GLOBENEWSWIRE
LAVA Therapeutics Announces Collaboration with Merck & Co.
25 Jan 2024 //
GLOBENEWSWIRE
Lava Therapeutics Reports Third Quarter 2023 Financial Results
16 Nov 2023 //
GLOBENEWSWIRE
LAVA to Participate in H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Lava Therapeutics makes cuts to its headcount
22 Aug 2023 //
ENDPTS
LAVA to Participate in the H.C. Wainwright Immune Cell Engager Conference
14 Aug 2023 //
GLOBENEWSWIRE
LAVA winds down bispecific trial; Blue Water buys 6 marketed drugs for $8.5M
14 Jun 2023 //
ENDPTS
LAVA Provides Updates on Clinical Programs and Extends the Cash Runway
14 Jun 2023 //
GLOBENEWSWIRE
LAVA Provides Business Update and Reports First Quarter 2023 Financial Results
08 Jun 2023 //
GLOBENEWSWIRE
LAVA Announces Selection of T-Cell Engager Antibody to Move Toward Clinical Development
01 Jun 2023 //
GLOBENEWSWIRE
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
LAVA Announces Annual Meeting of Shareholders
30 May 2023 //
GLOBENEWSWIRE
Lava Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
11 Apr 2023 //
GLOBENEWSWIRE
LAVA Announces Appointment of Christy J. Oliger to its Board of Directors
09 Mar 2023 //
GLOBENEWSWIRE
LAVA Announces Initial Data from Ongoing Phase 1/2a Clinical Trial of LAVA-1207
16 Feb 2023 //
GLOBENEWSWIRE
LAVA Therapeutics to Present at 2023 SVB Securities Global Biopharma Conference
09 Feb 2023 //
GLOBENEWSWIRE
LAVA Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
06 Feb 2023 //
GLOBENEWSWIRE
LAVA Therapeutics to Present LAVA-1207 Clinical Data at 2023 ASCO GU Symposium
23 Jan 2023 //
GLOBENEWSWIRE
LAVA Therapeutics Announces Appointment of New Directors to the Board
06 Jan 2023 //
GLOBENEWSWIRE
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
GLOBENEWSWIRE
LAVA Announces Data from the Phase 1/2a Clinical Trial of LAVA-051 at ASH
10 Dec 2022 //
GLOBENEWSWIRE
LAVA Therapeutics Provides Business Update and Reports 3Q Financial Results
16 Nov 2022 //
GLOBENEWSWIRE
LAVA to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051
03 Nov 2022 //
GLOBENEWSWIRE
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
03 Nov 2022 //
GLOBENEWSWIRE
LAVA Therapeutics Announces Appointment of Fred M. Powell as CFO
01 Nov 2022 //
GLOBENEWSWIRE
LAVA Therapeutics Appoints Fred Powell as CFO
01 Nov 2022 //
PRESS RELEASE
LAVA to Present On-Mechanism Pharmacodynamics Data Ph 1/2a Trial of LAVA-051
07 Oct 2022 //
GLOBENEWSWIRE
Seagen pays Lava $50M for preclinical T-cell engager for cancer
27 Sep 2022 //
FIERCEBIOTECH
LAVA Therapeutics Provides Business Update and Reports 2Q
13 Sep 2022 //
GLOBENEWSWIRE
LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual GIC
07 Sep 2022 //
GLOBENEWSWIRE
LAVA Tx Highlights Encouraging Updates on Lead Program, LAVA-051, in CLL and MM
16 Jun 2022 //
GLOBENEWSWIRE
LAVA Therapeutics Announces Two Appointments to its Board of Directors
15 Jun 2022 //
GLOBENEWSWIRE
LAVA Therapeutics to Participate at the Jefferies Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
LAVA Tx to Present Initial PI/IIa Trial Dose Escalation Data of LAVA-051
01 Jun 2022 //
GLOBENEWSWIRE
LAVA Therapeutics Announces Annual Meeting of Shareholders
31 May 2022 //
GLOBENEWSWIRE
LAVA Therapeutics to Participate at the UBS Global Healthcare Conference
05 May 2022 //
GLOBENEWSWIRE
LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 ASCO
27 Apr 2022 //
GLOBENEWSWIRE
LAVA Tx Reports Fourth Quarter and Year End 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
LAVA Tx To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
10 Mar 2022 //
GLOBENEWSWIRE
LAVA Tx Presents Initial LAVA-051 Data at ESMO
07 Mar 2022 //
GLOBENEWSWIRE
LAVA Tx Treats First Patient in Phase 1/2a Clinical Trial of LAVA-1207
01 Feb 2022 //
GLOBENEWSWIRE
LAVA Tx Presents Preclinical Data on its Gammabody T Cell Engager Platform
18 Jan 2022 //
GLOBENEWSWIRE
LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan
20 Dec 2021 //
GLOBENEWSWIRE
LAVA & The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
11 Nov 2021 //
GLOBENEWSWIRE
LAVA to Participate in the 12th Annual Jefferies London Healthcare Conference
04 Nov 2021 //
GLOBENEWSWIRE
LAVA Therapeutics Provides Business Update and Reports Second Quarter Results
16 Aug 2021 //
GLOBENEWSWIRE
LAVA Therapeutics Announces Treatment of First Patient in Trial of LAVA-051
13 Jul 2021 //
GLOBENEWSWIRE
LAVA Therapeutics announced the start of the first patient in trial of LAVA-051
13 Jul 2021 //
GLOBENEWSWIRE
LAVA Therapeutics Provides Business Update & Reports Q1 Financial Results
20 May 2021 //
GLOBENEWSWIRE
Dutch cancer biotech LAVA Therapeutics sets terms for $101 million US IPO
18 Mar 2021 //
RENAISSANCE CAPITAL
LAVA to Present Preclinical Findings Supporting Anti-Tumor Activity
10 Mar 2021 //
PRESS RELEASE
Dutch cancer biotech LAVA Therapeutics files for a $100 million US IPO
03 Mar 2021 //
NASDAQ
Lava breaks silence with an $83M Series & two I/O programs set for the clinic
17 Sep 2020 //
ENDPTS
